Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
-
Published:2023-12
Issue:
Volume:Volume 14
Page:101-109
-
ISSN:1179-2728
-
Container-title:Lung Cancer: Targets and Therapy
-
language:en
-
Short-container-title:LCTT
Author:
Nagasaka MisakoORCID,
Ou Saihong IgnatiusORCID
Publisher
Informa UK Limited
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献